SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves.
COVID-19
Inflammatory bowel disease
Outcome
Pandemic
SARS-CoV-2
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
05 Jul 2023
05 Jul 2023
Historique:
received:
28
09
2022
accepted:
30
05
2023
medline:
7
7
2023
pubmed:
6
7
2023
entrez:
5
7
2023
Statut:
epublish
Résumé
In Italy, the incidence of SARS-CoV-2 infection peaked in April and November 2020, defining two pandemic waves of coronavirus disease 2019 (COVID-19). This study compared the characteristics and outcomes of patients with inflammatory bowel disease (IBD) and SARS-CoV-2 infections between pandemic waves. Observational longitudinal study of IBD patients with SARS-CoV-2 infection. Patients with established diagnoses of IBD and of SARS-CoV-2 infection were consecutively enrolled in two periods: (i) first wave, from 1 March 2020 to 31 May 2020; and (ii) second wave, from 15 September to 15 December 2020. We enrolled 937 IBD patients (219 in the first wave, 718 in the second wave). Patients of the first wave were older (mean ± SD: 46.3 ± 16.2 vs. 44.1 ± 15.4 years, p = 0.06), more likely to have ulcerative colitis (58.0% vs. 44.4%, p < 0.001) and comorbidities (48.9% vs. 38.9%; p < 0.01), and more frequently residing in Northern Italy (73.1% vs. 46.0%, p < 0.001) than patients of the second wave. There were no significant differences between pandemic waves in sex (male: 54.3% vs. 53.3%, p = 0.82) or frequency of active IBD (44.3% vs. 39.0%, p = 0.18). The rates of negative outcomes were significantly higher in the first than second wave: pneumonia (27.8% vs. 11.7%, p < 0.001), hospital admission (27.4% vs. 9.7%, p < 0.001), ventilatory support (11.9% vs. 5.4%, p < 0.003) and death (5.5% vs. 1.8%, p < 0.007). Between the first and second SARS-CoV-2 pandemic waves, demographic, clinical and geographical features of IBD patients were different as were the symptoms and outcomes of infection. These differences are likely due to the different epidemiological situations and diagnostic possibilities between the two waves.
Sections du résumé
BACKGROUND
BACKGROUND
In Italy, the incidence of SARS-CoV-2 infection peaked in April and November 2020, defining two pandemic waves of coronavirus disease 2019 (COVID-19). This study compared the characteristics and outcomes of patients with inflammatory bowel disease (IBD) and SARS-CoV-2 infections between pandemic waves.
METHODS
METHODS
Observational longitudinal study of IBD patients with SARS-CoV-2 infection. Patients with established diagnoses of IBD and of SARS-CoV-2 infection were consecutively enrolled in two periods: (i) first wave, from 1 March 2020 to 31 May 2020; and (ii) second wave, from 15 September to 15 December 2020.
RESULTS
RESULTS
We enrolled 937 IBD patients (219 in the first wave, 718 in the second wave). Patients of the first wave were older (mean ± SD: 46.3 ± 16.2 vs. 44.1 ± 15.4 years, p = 0.06), more likely to have ulcerative colitis (58.0% vs. 44.4%, p < 0.001) and comorbidities (48.9% vs. 38.9%; p < 0.01), and more frequently residing in Northern Italy (73.1% vs. 46.0%, p < 0.001) than patients of the second wave. There were no significant differences between pandemic waves in sex (male: 54.3% vs. 53.3%, p = 0.82) or frequency of active IBD (44.3% vs. 39.0%, p = 0.18). The rates of negative outcomes were significantly higher in the first than second wave: pneumonia (27.8% vs. 11.7%, p < 0.001), hospital admission (27.4% vs. 9.7%, p < 0.001), ventilatory support (11.9% vs. 5.4%, p < 0.003) and death (5.5% vs. 1.8%, p < 0.007).
CONCLUSION
CONCLUSIONS
Between the first and second SARS-CoV-2 pandemic waves, demographic, clinical and geographical features of IBD patients were different as were the symptoms and outcomes of infection. These differences are likely due to the different epidemiological situations and diagnostic possibilities between the two waves.
Identifiants
pubmed: 37407913
doi: 10.1186/s12876-023-02841-0
pii: 10.1186/s12876-023-02841-0
pmc: PMC10324268
doi:
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
230Investigateurs
Daniela Pugliese
(D)
Federica Furfaro
(F)
Giovanni Maconi
(G)
Monica Milla
(M)
Fabrizio Bossa
(F)
Alessandra Giuliano
(A)
Nicole Piazza
(N)
Gianpiero Manes
(G)
Alessandro Sartini
(A)
Andrea Buda
(A)
Federica Micheli
(F)
Valeria Ciardo
(V)
Giovanni Casella
(G)
Angelo Viscido
(A)
Giorgia Bodini
(G)
Valentina Casini
(V)
Alessandra Soriano
(A)
Arnaldo Amato
(A)
Laurino Grossi
(L)
Sara Onali
(S)
Matteo Rottoli
(M)
Rocco Spagnuolo
(R)
Stefania Baroni
(S)
Claudio Cortelezzi
(C)
Monia Baldoni
(M)
Marta Vernero
(M)
Franco Scaldaferri
(F)
Giovanni Maconi
(G)
Alessia Guarino
(A)
Andrea Palermo
(A)
Renata D'Incà
(R)
Maria Lia Scribano
(ML)
Livia Biancone
(L)
Lucio Carrozza
(L)
Marta Ascolani
(M)
Francesco Costa
(F)
Antonio Di Sabatino
(A)
Irene Zammarchi
(I)
Matteo Gottin
(M)
Francesco Simone Conforti
(FS)
Informations de copyright
© 2023. The Author(s).
Références
BMJ Open. 2021 Oct 4;11(10):e051164
pubmed: 34607868
Aliment Pharmacol Ther. 2021 Dec;54(11-12):1432-1441
pubmed: 34694009
J Crohns Colitis. 2021 Apr 6;15(4):529-539
pubmed: 33079178
Expert Rev Respir Med. 2021 Dec;15(12):1619-1625
pubmed: 34311634
Front Public Health. 2021 Jul 16;9:669209
pubmed: 34336767
Transbound Emerg Dis. 2021 Mar;68(2):213-215
pubmed: 32892500
Gut. 2020 Jul;69(7):1213-1217
pubmed: 32354990
PLoS One. 2021 Mar 31;16(3):e0248029
pubmed: 33788866
J Crohns Colitis. 2021 Apr 6;15(4):540-550
pubmed: 33035299
Aliment Pharmacol Ther. 2021 Jun;53(11):1236-1240
pubmed: 33961708
Lancet Reg Health Am. 2021 Nov;3:100041
pubmed: 34423331
Eur Rev Med Pharmacol Sci. 2021 Jan;25(1):9-10
pubmed: 33506947
Inflamm Bowel Dis. 2022 Nov 2;28(11):1687-1695
pubmed: 35032167
Euro Surveill. 2020 May;25(19):
pubmed: 32431289
J Infect. 2021 Jul;83(1):e32-e33
pubmed: 33932448
Lancet. 1980 Mar 8;1(8167):514
pubmed: 6102236
Aliment Pharmacol Ther. 2021 Jul;54(2):160-166
pubmed: 34110040
Travel Med Infect Dis. 2020 Mar - Apr;34:101623
pubmed: 32179124
Gastroenterology. 2020 Oct;159(4):1541-1544.e2
pubmed: 32479824
J Clin Exp Hepatol. 2022 May-Jun;12(3):876-886
pubmed: 34728983
Int J Cardiovasc Imaging. 2021 Nov;37(11):3181-3190
pubmed: 34460023
Int J Infect Dis. 2021 Apr;105:374-376
pubmed: 33684560
Gastroenterology. 2020 Aug;159(2):481-491.e3
pubmed: 32425234
Gastroenterology. 2020 Oct;159(4):1575-1578.e4
pubmed: 32522507
Inflamm Bowel Dis. 2020 Oct 23;26(11):e138-e139
pubmed: 32949238
N Engl J Med. 1987 Dec 24;317(26):1625-9
pubmed: 3317057
United European Gastroenterol J. 2021 Mar;9(2):159-176
pubmed: 33210980